Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis.

The initial stimulus for inflammatory cell recruitment and the mechanisms responsible for the perpetuation and evolution of chronic inflammation, granulation tissue formation, and fibrosis have not been fully elucidated. Although interleukin (IL)-13, a Th2 cytokine, has been shown to have direct effects on fibroblasts that support fibroproliferation, it is also a potent inducer of a novel CC chemokine, C10, which is chemotactic for mononuclear phagocytes. The macrophage/mononuclear phagocyte has been shown to have a role in the pathogenesis of pulmonary fibrosis, serving as an important source of growth factors that regulate extracellular matrix synthesis. In this study we demonstrate that IL-13 and C10 are elevated in the pathogenesis of bleomycin-induced pulmonary fibrosis. Neutralization of IL-13, but not IL-4, attenuated bleomycin-induced pulmonary fibrosis and levels of C10, suggesting that IL-13 has an important role in the development of pulmonary fibrosis. IL-13 is a potent inducer of C10 in vivo, and neutralization of C10 attenuated bleomycin-induced pulmonary fibrosis and intrapulmonary macrophage numbers. This suggests that IL-13 has a role in the development of pulmonary fibrosis that is independent of its direct effect on fibroblasts and is evidence for an interaction between Th2 cytokines and specific CC chemokines.

[1]  B. Ma,et al.  IL-13-Induced Chemokine Responses in the Lung: Role of CCR2 in the Pathogenesis of IL-13-Induced Inflammation and Remodeling1 , 2002, The Journal of Immunology.

[2]  T. Moore,et al.  Protection from Pulmonary Fibrosis in the Absence of CCR2 Signaling1 , 2001, The Journal of Immunology.

[3]  I. S. Dunn,et al.  Tracking membrane and secretory immunoglobulin α heavy chain mRNA variation during B‐cell differentiation by real‐time quantitative polymerase chain reaction , 2001, Immunology and cell biology.

[4]  R. Homer,et al.  Interleukin-13 Induces Tissue Fibrosis by Selectively Stimulating and Activating Transforming Growth Factor β1 , 2001, The Journal of experimental medicine.

[5]  S. Phan,et al.  Lung interleukin-4 gene expression in a murine model of bleomycin-induced pulmonary fibrosis. , 2001, Cytokine.

[6]  M. Burdick,et al.  IL-12 attenuates bleomycin-induced pulmonary fibrosis. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[7]  L. Lichtenstein,et al.  Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. , 2000, The Journal of pharmacology and experimental therapeutics.

[8]  M. Prystowsky,et al.  Divergent regulation of the murine CC chemokine C10 by Th(1) and Th(2) cytokines. , 2000, Cytokine.

[9]  M. Burdick,et al.  IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. , 1999, Journal of immunology.

[10]  S. Romagnani Th1/Th2 cells. , 1999, Inflammatory bowel diseases.

[11]  V. Petkov,et al.  A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. , 1999, The New England journal of medicine.

[12]  A. Singer,et al.  Cutaneous wound healing. , 1999, The New England journal of medicine.

[13]  M. Prystowsky,et al.  Sustained high-level production of murine chemokine C10 during chronic inflammation. , 1999, Cytokine.

[14]  D. Taub,et al.  Immunomodulatory role of C10 chemokine in a murine model of allergic bronchopulmonary aspergillosis. , 1999, Journal of immunology.

[15]  M. Burdick,et al.  Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. , 1999, Journal of immunology.

[16]  S. Henriksen,et al.  C10 is a novel chemokine expressed in experimental inflammatory demyelinating disorders that promotes recruitment of macrophages to the central nervous system. , 1999, The American journal of pathology.

[17]  R. Homer,et al.  Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. , 1999, The Journal of clinical investigation.

[18]  S. Kunkel,et al.  Erratum: Mycobacterial and schistosomal antigen-elicited granuloma formation in IFN-γ and IL-4 knockout mice: Analysis of Local and regional cytokine and chemokine networks (Journal of Immunology (1997) 159 (3565- 3573)) , 1999 .

[19]  D B Corry,et al.  Requirement for IL-13 independently of IL-4 in experimental asthma. , 1998, Science.

[20]  D D Donaldson,et al.  Interleukin-13: central mediator of allergic asthma , 1998 .

[21]  G. Vogel Interleukin-13's Key Role in Asthma Shown , 1998, Science.

[22]  T. Schall,et al.  Molecular Cloning and Functional Characterization of Human MIP-1δ, a New C–C Chemokine Related to Mouse CCF-18 and C10 , 1998, Journal of Clinical Immunology.

[23]  S. Kunkel,et al.  Mycobacterial and schistosomal antigen-elicited granuloma formation in IFN-gamma and IL-4 knockout mice: analysis of local and regional cytokine and chemokine networks. , 1997, Journal of immunology.

[24]  T. Standiford,et al.  Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumonia , 1996, Infection and immunity.

[25]  R. Strieter,et al.  C-C chemokines: novel mediators of the profibrotic inflammatory response to bleomycin challenge. , 1996, American journal of respiratory cell and molecular biology.

[26]  D. Elliott,et al.  The granulomatous response in murine Schistosomiasis mansoni does not switch to Th1 in IL-4-deficient C57BL/6 mice. , 1996, Journal of immunology.

[27]  R. Whyte,et al.  Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases , 1996, The Journal of experimental medicine.

[28]  B. Stripp,et al.  Phenotypic and physiologic characterization of transgenic mice expressing interleukin 4 in the lung: lymphocytic and eosinophilic inflammation without airway hyperreactivity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. Burdick,et al.  Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. , 1996, The Journal of clinical investigation.

[30]  D. Taub,et al.  The chemokine C10: immunological and functional analysis of the sequence encoded by the novel second exon. , 1996, Cytokine.

[31]  R. Fernandez-Botran,et al.  Schistosoma mansoni in IL-4-deficient mice. , 1996, International immunology.

[32]  N. Martinet,et al.  The role of cytokines in human lung fibrosis. , 1996, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[33]  D. Lamb,et al.  A type 2 (Th2‐like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA) , 1995, Clinical and experimental immunology.

[34]  S. Phan New strategies for treatment of pulmonary fibrosis. , 1995, Thorax.

[35]  M. Burdick,et al.  Production and function of murine macrophage inflammatory protein-1 alpha in bleomycin-induced lung injury. , 1994, Journal of immunology.

[36]  S. Phan,et al.  Lung monocyte chemoattractant protein-1 gene expression in bleomycin-induced pulmonary fibrosis. , 1994, Journal of immunology.

[37]  A. Orlofsky,et al.  Selective induction of the beta chemokine C10 by IL-4 in mouse macrophages. , 1994, Journal of immunology.

[38]  C. Kozak,et al.  The gene for C10, a member of the beta-chemokine family, is located on mouse chromosome 11 and contains a novel second exon not found in other chemokines. , 1993, DNA and cell biology.

[39]  J. Brieland,et al.  Expression of monocyte chemoattractant protein-1 (MCP-1) by rat alveolar macrophages during chronic lung injury. , 1993, American Journal of Respiratory Cell and Molecular Biology.

[40]  M. Jordana,et al.  Cytokines and pulmonary fibrosis. , 1993, Thorax.

[41]  R. de Waal Malefyt,et al.  Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[42]  G. Raghu,et al.  Production of collagenase and tissue inhibitor of metalloproteinases by fibroblasts derived from normal and fibrotic human lungs. , 1992, Chest.

[43]  M. Berger,et al.  Novel expression pattern of a new member of the MIP-1 family of cytokine-like genes. , 1991, Cell regulation.

[44]  S. Kalinka,et al.  Measurement of interleukin‐6 in bronchoalveolar lavage fluid by radioimmunoassay: differences between patients with interstitial lung disease and control subjects , 1991, Clinical and experimental immunology.

[45]  Chandler Db Possible mechanisms of bleomycin-induced fibrosis. , 1990 .

[46]  P. Vassalli,et al.  Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis , 1989, The Journal of experimental medicine.

[47]  W. Paul,et al.  Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant of that line (CT.4S). , 1989, Journal of immunology.

[48]  S. Yasui,et al.  Bleomycin-stimulated hamster alveolar macrophages release interleukin-1. , 1988, The American journal of pathology.

[49]  John F. Murray,et al.  Textbook of Respiratory Medicine , 1988 .

[50]  M. Jordana,et al.  Spontaneous in vitro release of alveolar-macrophage cytokines after the intratracheal instillation of bleomycin in rats. Characterization and kinetic studies. , 1988, The American review of respiratory disease.

[51]  R. Chapela,et al.  Concentration, biosynthesis and degradation of collagen in idiopathic pulmonary fibrosis. , 1986, Thorax.

[52]  Bowden Dh Unraveling pulmonary fibrosis: the bleomycin model. , 1984 .

[53]  R. Crystal,et al.  Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract. , 1984, The New England journal of medicine.

[54]  R. Crystal,et al.  Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts). , 1984, The New England journal of medicine.

[55]  Arnold Simanowitz,et al.  international consensus statement , 2000 .

[56]  David A. Lynch,et al.  Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .

[57]  A. Ohta,et al.  Determination of various cytokines and type III procollagen aminopeptide levels in bronchoalveolar lavage fluid of the patients with pulmonary fibrosis: inverse correlation between type III procollagen aminopeptide and interferon-gamma in progressive patients. , 1995, British journal of rheumatology.

[58]  R. Thompson,et al.  Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. , 1993, Cytokine.

[59]  S. Romagnani Induction of TH1 and TH2 responses: a key role for the 'natural' immune response? , 1992, Immunology today.

[60]  S. Kunkel,et al.  Lung cytokine production in bleomycin-induced pulmonary fibrosis. , 1992, Experimental lung research.